Frequently Asked Questions
The market is segmented based on , By Type (Furious Rabies, Paralytic Rabies, Others), Treatment (Rabies Immunoglobulin, Vaccines, Antiviral drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
.
The Global Rabies Prophylaxis Market size was valued at USD 1.70 USD Billion in 2021.
The Global Rabies Prophylaxis Market is projected to grow at a CAGR of 4.2% during the forecast period of 2022 to 2029.
The major players operating in the market include F. Hoffmann, La Roche , Mylan N.V., Teva Pharmaceutical Industries , Sanofi, Pfizer , GlaxoSmithKline plc, Novartis AG, Merck & Co., Allergan, AstraZeneca, Johnson & Johnson Private Limited, Bristol Myers Squibb Company, Bayer AG, Dr. Reddy's Laboratories , Eli Lilly and Company, Serum Institute of India Pvt. , Elanco, Virbac, Zoetis, Cadila Pharmaceuticals.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
